Simon H Mead

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4467002/publications.pdf

Version: 2024-02-01

218 papers 27,739 citations

67 h-index 156 g-index

248 all docs 248
docs citations

times ranked

248

24316 citing authors

#	Article	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
2	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
3	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
4	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
5	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039
6	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
7	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
8	A stop-codon mutation in the BRI gene associated with familial British dementia. Nature, 1999, 399, 776-781.	27.8	467
9	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	10.2	432
10	Evidence for human transmission of amyloid- \hat{l}^2 pathology and cerebral amyloid angiopathy. Nature, 2015, 525, 247-250.	27.8	418
11	Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain, 2012, 135, 736-750.	7.6	392
12	Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology, 2016, 86, 1736-1743.	1.1	383
13	Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain, 2015, 138, 3673-3684.	7.6	359
14	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology, 2016, 87, 1329-1336.	1.1	354
15	Balancing Selection at the Prion Protein Gene Consistent with Prehistoric Kurulike Epidemics. Science, 2003, 300, 640-643.	12.6	347
16	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347
17	Kuru in the 21st centuryâ€"an acquired human prion disease with very long incubation periods. Lancet, The, 2006, 367, 2068-2074.	13.7	345
18	Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain, 2011, 134, 2565-2581.	7.6	306

#	Article	IF	Citations
19	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
20	Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK Population. American Journal of Human Genetics, 2013, 92, 345-353.	6.2	297
21	Prion disease genetics. European Journal of Human Genetics, 2006, 14, 273-281.	2.8	282
22	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 291-301.	10.2	270
23	<i>C9orf72</i> expansions are the most common genetic cause of Huntington disease phenocopies. Neurology, 2014, 82, 292-299.	1.1	252
24	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
25	Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ, The, 2013, 347, f5675-f5675.	6.0	246
26	Progressive logopenic/phonological aphasia: Erosion of the language network. NeuroImage, 2010, 49, 984-993.	4.2	223
27	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain, 2008, 131, 706-720.	7.6	222
28	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	7.7	222
29	Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neurolmage, 2010, 53, 1070-1076.	4.2	209
30	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.1	204
31	Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet, The, 2011, 377, 487-493.	13.7	192
32	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
33	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
34	Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathology and Applied Neurobiology, 2015, 41, 858-881.	3.2	168
35	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. Lancet Neurology, The, 2016, 15, 1326-1335.	10.2	163
36	A Novel Protective Prion Protein Variant that Colocalizes with Kuru Exposure. New England Journal of Medicine, 2009, 361, 2056-2065.	27.0	157

#	Article	IF	CITATIONS
37	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
38	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	3.1	151
39	Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurology, The, 2021, 20, 235-246.	10.2	151
40	Genetic Analysis of Inherited Leukodystrophies. JAMA Neurology, 2013, 70, 875.	9.0	147
41	A naturally occurring variant of the human prion protein completely prevents prion disease. Nature, 2015, 522, 478-481.	27.8	144
42	Non-photic phase shifting of the circadian activity rhythm of Syrian hamsters: the relative potency of arousal and melatonin. Brain Research, 1992, 591, 20-26.	2.2	141
43	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
44	Genetic risk factors for variant Creutzfeldt–Jakob disease: a genome-wide association study. Lancet Neurology, The, 2009, 8, 57-66.	10.2	131
45	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
46	Variant Creutzfeldt–Jakob Disease in a Patient with Heterozygosity at <i>PRNP</i> Codon 129. New England Journal of Medicine, 2017, 376, 292-294.	27.0	127
47	Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain, 2008, 131, 2632-2646.	7.6	126
48	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathologica, 2013, 126, 401-409.	7.7	126
49	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	7.7	123
50	A Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy. New England Journal of Medicine, 2013, 369, 1904-1914.	27.0	113
51	A common single-nucleotide variant in T is strongly associated with chordoma. Nature Genetics, 2012, 44, 1185-1187.	21.4	112
52	Familial British dementia with amyloid angiopathy. Brain, 2000, 123, 975-991.	7.6	104
53	Inherited prion disease with six octapeptide repeat insertional mutation-molecular analysis of phenotypic heterogeneity. Brain, 2006, 129, 2297-2317.	7.6	103
54	Profiles of white matter tract pathology in frontotemporal dementia. Human Brain Mapping, 2014, 35, 4163-4179.	3.6	102

#	Article	IF	CITATIONS
55	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
56	Sporadicâ€"but Not Variantâ€"Creutzfeldt-Jakob Disease Is Associated with Polymorphisms Upstream of PRNP Exon 1. American Journal of Human Genetics, 2001, 69, 1225-1235.	6.2	95
57	Variant CJD in an individual heterozygous for PRNP codon 129. Lancet, The, 2009, 374, 2128.	13.7	94
58	<i>R47H TREM2</i> variant increases risk of typical earlyâ€onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's and Dementia, 2014, 10, 602.	0.8	94
59	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
60	latrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain, 2015, 138, 3386-3399.	7.6	92
61	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
62	Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimer's Research and Therapy, 2012, 4, 41.	6.2	89
63	PRNP allelic series from 19 years of prion protein gene sequencing at the MRC Prion Unit. Human Mutation, 2010, 31, E1551-E1563.	2.5	85
64	Genetics of Prion Disease. Topics in Current Chemistry, 2011, 305, 1-22.	4.0	84
65	Tau, prions and $\hat{Al^2}$: the triad of neurodegeneration. Acta Neuropathologica, 2011, 121, 5-20.	7.7	84
66	Evidence of amyloid- \hat{l}^2 cerebral amyloid angiopathy transmission through neurosurgery. Acta Neuropathologica, 2018, 135, 671-679.	7.7	80
67	The Medical Research Council Prion Disease Rating Scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain, 2013, 136, 1116-1127.	7.6	77
68	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
69	Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Human Molecular Genetics, 2012, 21, 1897-1906.	2.9	73
70	Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology, 2019, 93, e125-e134.	1.1	73
71	Genetics of prion diseases. Current Opinion in Genetics and Development, 2013, 23, 345-351.	3.3	69
72	CJD mimics and chameleons. Practical Neurology, 2017, 17, 113-121.	1.1	69

#	Article	IF	CITATIONS
73	Imaging and CSF analyses effectively distinguish CJD from its mimics. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 461-466.	1.9	69
74	Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 955-961.	1.9	68
75	Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiology of Aging, 2012, 33, 426.e13-426.e21.	3.1	67
76	HECTD2 Is Associated with Susceptibility to Mouse and Human Prion Disease. PLoS Genetics, 2009, 5, e1000383.	3.5	66
77	A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3725-3739.	4.0	65
78	Association of a null allele of SPRN with variant Creutzfeldt-Jakob disease. Journal of Medical Genetics, 2008, 45, 813-817.	3.2	65
79	Genetic Factors in Mammalian Prion Diseases. Annual Review of Genetics, 2019, 53, 117-147.	7.6	63
80	Kuru prions and sporadic Creutzfeldt–Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3885-3890.	7.1	62
81	MRI findings are often missed in the diagnosis of Creutzfeldt-Jakob disease. BMC Neurology, 2012, 12, 153.	1.8	61
82	Evolution of Diffusion-Weighted Magnetic Resonance Imaging Signal Abnormality in Sporadic Creutzfeldt-Jakob Disease, With Histopathological Correlation. JAMA Neurology, 2016, 73, 76.	9.0	60
83	Examination of the human prion protein-like gene Doppel for genetic susceptibility to sporadic and variant Creutzfeldt–Jakob disease. Neuroscience Letters, 2000, 290, 117-120.	2.1	59
84	Validation of next-generation sequencing technologies in genetic diagnosis of dementia. Neurobiology of Aging, 2014, 35, 261-265.	3.1	59
85	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
86	Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Annals of Neurology, 2019, 85, 284-290.	5. 3	54
87	The Role of Variation at \hat{Al}^2 PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	2.6	53
88	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3140-3151.	3.1	53
89	Parietal Lobe Deficits in Frontotemporal Lobar Degeneration Caused by a Mutation in the Progranulin Gene. Archives of Neurology, 2008, 65, 506.	4.5	52
90	Genetic Variability in CLU and Its Association with Alzheimer's Disease. PLoS ONE, 2010, 5, e9510.	2.5	52

#	Article	IF	CITATIONS
91	Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test. JAMA Neurology, 2014, 71, 421.	9.0	51
92	The C9ORF72 expansion mutation: gene structure, phenotypic and diagnostic issues. Acta Neuropathologica, 2014, 127, 319-332.	7.7	51
93	Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiology of Aging, 2015, 36, 546.e1-546.e7.	3.1	48
94	Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 692-694.	1.9	48
95	Potential human transmission of amyloid \hat{l}^2 pathology: surveillance and risks. Lancet Neurology, The, 2020, 19, 872-878.	10.2	46
96	Mapping the progression of progranulin-associated frontotemporal lobar degeneration. Nature Clinical Practice Neurology, 2008, 4, 455-460.	2.5	45
97	No association of PGRN 3′UTR rs5848 in frontotemporal lobar degeneration. Neurobiology of Aging, 2011, 32, 754-755.	3.1	42
98	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	10.2	42
99	A new prion disease: relationship with central and peripheral amyloidoses. Nature Reviews Neurology, 2015, 11, 90-97.	10.1	41
100	Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. JAMA Neurology, 2016, 73, 447.	9.0	41
101	Ascertainment Bias Causes False Signal of Anticipation in Genetic Prion Disease. American Journal of Human Genetics, 2014, 95, 371-382.	6.2	40
102	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the ⟨scp⟩GENFI⟨/scp⟩ cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	3.7	39
103	Behavioral and Psychiatric Symptoms in Prion Disease. American Journal of Psychiatry, 2014, 171, 265-274.	7.2	38
104	Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2008, 459, 197-227.	0.9	38
105	Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurology, The, 2022, 21, 342-354.	10.2	38
106	Genetic susceptibility, evolution and the kuru epidemic. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3741-3746.	4.0	37
107	A pathogenic <i>progranulin </i> mutation and <scp><i>C9orf72</i> </scp> repeat expansion in a family with frontotemporal dementia. Neuropathology and Applied Neurobiology, 2014, 40, 502-513.	3.2	37
108	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. Journal of Alzheimer's Disease, 2013, 35, 199-212.	2.6	36

#	Article	IF	Citations
109	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. Neurobiology of Aging, 2016, 46, 236.e1-236.e6.	3.1	34
110	Review: Fluid biomarkers in the human prion diseases. Molecular and Cellular Neurosciences, 2019, 97, 81-92.	2.2	34
111	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. Neurobiology of Aging, 2009, 30, 656-665.	3.1	33
112	Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 758.e1-758.e7.	3.1	32
113	Recent US Case of Variant Creutzfeldt-Jakob Disease—Global Implications. Emerging Infectious Diseases, 2015, 21, 750-759.	4.3	32
114	Altered body schema processing in frontotemporal dementia with C9ORF72 mutations. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1016-1023.	1.9	31
115	Creutzfeldt-Jakob Disease, Prion Protein Gene Codon 129VV, and a Novel PrPSc Type in a Young British Woman. Archives of Neurology, 2007, 64, 1780.	4.5	30
116	A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes. Journal of Neurology, 2011, 258, 1494-1496.	3.6	30
117	Prevalence in Britain of abnormal prion protein in human appendices before and after exposure to the cattle BSE epizootic. Acta Neuropathologica, 2020, 139, 965-976.	7.7	30
118	Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Molecular Psychiatry, 2021, 26, 5955-5966.	7.9	30
119	Inherited prion disease with 4-octapeptide repeat insertion: disease requires the interaction of multiple genetic risk factors. Brain, 2011, 134, 1829-1838.	7.6	29
120	In vitro screen of prion disease susceptibility genes using the scrapie cell assay. Human Molecular Genetics, 2014, 23, 5102-5108.	2.9	29
121	The clinical, neuroanatomical, and neuropathologic phenotype of <i>TBK1</i> â€associated frontotemporal dementia: A longitudinal case report. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 75-81.	2.4	28
122	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
123	Genetic testing in dementia — utility and clinical strategies. Nature Reviews Neurology, 2021, 17, 23-36.	10.1	26
124	latrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 693-700.	1.9	26
125	Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine. JAMA Neurology, 2016, 73, 1454.	9.0	25
126	A highly specific blood test for vCJD. Blood, 2014, 123, 452-453.	1.4	24

#	Article	IF	Citations
127	The cognitive profile of prion disease: a prospective clinical and imaging study. Annals of Clinical and Translational Neurology, 2015, 2, 548-558.	3.7	24
128	Quantitative EEG parameters correlate with the progression of human prion diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1061-1067.	1.9	24
129	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
130	Predictive testing for inherited prion disease: report of 22 years experience. European Journal of Human Genetics, 2014, 22, 1351-1356.	2.8	23
131	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. PLoS ONE, 2019, 14, e0218111.	2.5	23
132	Prion protein gene M232R variation is probably an uncommon polymorphism rather than a pathogenic mutation. Brain, 2012, 135, e209-e209.	7.6	21
133	A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis. Nature Communications, 2020, 11, 3960.	12.8	20
134	Bank vole prion protein extends the use of RT-QuIC assays to detect prions in a range of inherited prion diseases. Scientific Reports, 2021, 11, 5231.	3.3	20
135	Successful amplification of degraded DNA for use with high-throughput SNP genotyping platforms. Human Mutation, 2008, 29, 1452-1458.	2.5	19
136	Heterozygosity at Polymorphic Codon 219 in Variant Creutzfeldt-Jakob Disease. Archives of Neurology, 2010, 67, 1021-3.	4.5	19
137	A small deletion in C9orf72 hides a proportion of expansion carriers in FTLD. Neurobiology of Aging, 2015, 36, 1601.e1-1601.e5.	3.1	19
138	Altered DNA methylation profiles in blood from patients with sporadic Creutzfeldt–Jakob disease. Acta Neuropathologica, 2020, 140, 863-879.	7.7	18
139	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.7	17
140	Variant Creutzfeldt-Jakob Disease With Extremely Low Lymphoreticular Deposition of Prion Protein. JAMA Neurology, 2014, 71, 340.	9.0	17
141	Methods for Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2017, 1658, 311-346.	0.9	17
142	Alzheimer's disease neuropathological change three decades after iatrogenic amyloid-β transmission. Acta Neuropathologica, 2021, 142, 211-215.	7.7	17
143	Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. Brain, 2019, 142, 760-770.	7.6	16
144	Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	7.6	16

#	Article	IF	CITATIONS
145	The Presenilin 1 P264L Mutation Presenting as non-Fluent/Agrammatic Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2013, 36, 239-243.	2.6	15
146	Prion protein ($\langle i \rangle$ PRNP $\langle i \rangle$) genotypes in frontotemporal lobar degeneration syndromes. Annals of Neurology, 2006, 60, 616-616.	5.3	14
147	Empowering Better Endâ€ofâ€Life Dementia Care (EMBEDâ€Care): A mixed methods protocol to achieve integrated personâ€centred care across settings. International Journal of Geriatric Psychiatry, 2020, 35, 820-832.	2.7	13
148	Spontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSS. PLoS Biology, 2020, 18, e3000725.	5.6	13
149	Genetic risk factors for Creutzfeldt-Jakob disease. Neurobiology of Disease, 2020, 142, 104973.	4.4	12
150	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
151	First Report of Creutzfeldt-Jakob Disease Occurring in 2 Siblings Unexplained by PRNPMutation. Journal of Neuropathology and Experimental Neurology, 2008, 67, 838-841.	1.7	11
152	HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q. BMC Medical Genetics, 2009, 10, 90.	2.1	11
153	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
154	Magnetization transfer ratio may be a surrogate of spongiform change in human prion diseases. Brain, 2010, 133, 3058-3068.	7.6	10
155	The language disorder of prion disease is characteristic of a dynamic aphasia and is rarely an isolated clinical feature. PLoS ONE, 2018, 13, e0190818.	2.5	10
156	Exome sequencing reveals a novel partial deletion in the progranulin gene causing primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1411-1412.	1.9	9
157	The TMEM106B risk allele is associated with lower cortical volumes in a clinically diagnosed frontotemporal dementia cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 997-998.	1.9	9
158	Evaluating the causality of novel sequence variants in the prion protein gene by example. Neurobiology of Aging, 2018, 71, 265.e1-265.e7.	3.1	9
159	Assessing initial MRI reports for suspected CJD patients. Journal of Neurology, 2022, 269, 4452-4458.	3.6	9
160	11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt–Jakob disease: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 340-341.	1.9	8
161	Neuroanatomical correlates of prion disease progression - a 3T longitudinal voxel-based morphometry study. NeuroImage: Clinical, 2017, 13, 89-96.	2.7	8
162	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8

#	Article	lF	Citations
163	The Future of Seed Amplification Assays and Clinical Trials. Frontiers in Aging Neuroscience, 0, 14, .	3.4	8
164	Filamentous white matter prion protein deposition is a distinctive feature of multiple inherited prion diseases. Acta Neuropathologica Communications, 2013, 1, 8.	5.2	7
165	Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process. Neurolmage: Clinical, 2019, 24, 102051.	2.7	7
166	Rare structural genetic variation in human prion diseases. Neurobiology of Aging, 2015, 36, 2004.e1-2004.e8.	3.1	6
167	Clinical trials. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 431-444.	1.8	6
168	Familial Creutzfeldt-Jakob disease in an Indian kindred. Annals of Indian Academy of Neurology, 2019, 22, 458.	0.5	6
169	Enteral feeding is associated with longer survival in the advanced stages of prion disease. Brain Communications, 2019, 1, fcz012.	3.3	5
170	Case report of homozygous E200D mutation of PRNP in apparently sporadic Creutzfeldt-Jakob disease. BMC Neurology, 2021, 21, 248.	1.8	5
171	Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 404-412.	1.9	5
172	Gene expression and epigenetic markers of prion diseases. Cell and Tissue Research, 2022, , 1.	2.9	5
173	Comment on validation of diagnostic criteria for variant Creutzfeldtâ€Jakob disease. Annals of Neurology, 2011, 69, 212-212.	5.3	4
174	Genome wide association studies and prion disease. Prion, 2011, 5, 154-160.	1.8	4
175	A novel prion protein variant in a patient with semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 890-892.	1.9	4
176	Reply to: Intrinsic Toxicity of Antibodies to the Globular Domain of the Prion Protein. Biological Psychiatry, 2018, 84, e53-e54.	1.3	4
177	The most problematic symptoms of prion disease – an analysis of carer experiences. International Psychogeriatrics, 2019, 31, 1181-1190.	1.0	4
178	Characterization of Prion Disease Associated with a Two-Octapeptide Repeat Insertion. Viruses, 2021, 13, 1794.	3.3	4
179	Novel regulators of PrPC biosynthesis revealed by genome-wide RNA interference. PLoS Pathogens, 2021, 17, e1010013.	4.7	4
180	NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression. Cells, 2021, 10, 3514.	4.1	4

#	Article	IF	CITATIONS
181	Prion protein gene mutation detection using long-read Nanopore sequencing. Scientific Reports, 2022, 12, 8284.	3.3	4
182	Variants of PLCXD3 are not associated with variant or sporadic Creutzfeldt-Jakob disease in a large international study. BMC Medical Genetics, 2016, 17, 28.	2.1	3
183	Preclinical biomarkers of prion infection and neurodegeneration. Current Opinion in Neurobiology, 2020, 61, 82-88.	4.2	3
184	Estimation of the number of inherited prion disease mutation carriers in the UK. European Journal of Human Genetics, 2022, 30, 1167-1170.	2.8	3
185	Prevalence and Treatments of Movement Disorders in Prion Diseases: A Longitudinal Cohort Study. Movement Disorders, 2022, 37, 1893-1903.	3.9	3
186	Clinical trials and methodological problems in prion diseases – Authors' reply. Lancet Neurology, The, 2009, 8, 782-783.	10.2	2
187	PATU2 Novel truncation mutation of PRNP causes chronic diarrhoea, sensory neuropathy and autonomic failure associated with prion protein deposition in the cerebral blood vessels and small bowel. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e24-e24.	1.9	2
188	The Intractable Puzzle of Sporadic Creutzfeldt-Jakob Disease in Very Young People. Neurology, 2021, 97, 801-802.	1.1	2
189	PAW35 Anti-prion protein monoclonal antibodies at low doses effectively treat prion disease in mice without side-effects. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e33-e33.	1.9	1
190	How does the genetic assassin select its neuronal target?. Mammalian Genome, 2011, 22, 139-147.	2.2	1
191	Developing early diagnostics for prion diseases. Neurodegenerative Disease Management, 2013, 3, 53-60.	2.2	1
192	PROBING FTD GENETICS WITH NEXT-GENERATION SEQUENCING. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.198-e1.	1.9	1
193	Transmissible Spongiform Encephalopathies of Humans and Animals. , 2017, , 214-220.e2.		1
194	Detection of Creutzfeldt-Jakob disease prions in skin: implications for healthcare. Genome Medicine, 2018, 10, 22.	8.2	1
195	Putaminal diffusion tensor imaging measures predict disease severity across human prion diseases. Brain Communications, 2020, 2, fcaa032.	3.3	1
196	Cognitive decline heralds onset of symptomatic inherited prion disease. Brain, 2021, 144, 989-998.	7.6	1
197	A novel presenilin 1 duplication mutation (lle168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. Neurobiology of Aging, 2021, 103, 137.e1-137.e5.	3.1	1
198	Gaussian Processes with optimal kernel construction for neuro-degenerative clinical onset prediction. , 2018, , .		1

#	Article	IF	CITATIONS
199	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
200	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
201	PAW23 Voxel-based analysis of magnetisation transfer ratio as a potential biomarker in prion diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e30-e30.	1.9	0
202	POD04 Analysis of eight rating scales supports the use of functional outcome measures in prion disease clinical trials: experience from the PRION-1 trial and the National Prion Monitoring cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e43-e43.	1.9	0
203	O1â€05â€01: Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features. Alzheimer's and Dementia, 2012, 8, P92.	0.8	O
204	Blood Test for Variant Creutzfeldt-Jakob Diseaseâ€"Reply. JAMA Neurology, 2014, 71, 1054.	9.0	0
205	Inherited mtDNA variations are not strong risk factors in human prion disease. Neurobiology of Aging, 2015, 36, 2908.e1-2908.e3.	3.1	O
206	Use of Diffusion-Weighted Magnetic Resonance Imaging in Sporadic Creutzfeldt-Jakob Disease—Reply. JAMA Neurology, 2016, 73, 1154.	9.0	0
207	RARE STRUCTURAL GENETIC VARIATION IN HUMAN PRION DISEASES. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.21-e1.	1.9	O
208	ESTIMATING CAUSALITY OF THE NOVEL PRION PROTEIN GENE VARIANT T201S. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.136-e1.	1.9	0
209	J9â€Probing huntington's disease phenocopy syndromes with next-generation sequencing. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A78.2-A78.	1.9	O
210	[P2â€"347]: SQSTM1 MUTATIONS IN FRONTOTEMPORAL DEMENTIA ARE ASSOCIATED WITH ASYMMETRICAL FOCAL TEMPORAL LOBE ATROPHY. Alzheimer's and Dementia, 2017, 13, P755.	0.8	0
211	[ICâ€Pâ€052]: SQSTM1 MUTATIONS IN FRONTOTEMPORAL DEMENTIA ARE ASSOCIATED WITH ASYMMETRICAL FOCAL TEMPORAL LOBE ATROPHY. Alzheimer's and Dementia, 2017, 13, P43.	0.8	O
212	[P1â \in "335]: THEMES AND VARIATIONS IN PPA: A CLINICAL AND NEUROBIOLOGICAL ANALYSIS OF THE UCL COHORT. Alzheimer's and Dementia, 2017, 13, P384.	0.8	0
213	[O4–O2–O4]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.8	O
214	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.8	0
215	Marked abnormalities of plasma protein biomarkers in Creutzfeldt-Jakob disease (CJD). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1137-1137.	1.9	O
216	Prion diseases of humans and animals. , 2010, , 243-250.		0

#	Article	IF	CITATIONS
217	Chorea in Prion Diseases. , 2014, , 221-236.		0
218	Imaging biomarkers for the diagnosis of Prion disease. , 2018, , .		0